Please use this identifier to cite or link to this item:
https://doi.org/10.1155/2011/829129
Title: | Guillain-Barré syndrome animal model: The first proof of molecular mimicry in human autoimmune disorder | Authors: | Yuki, N. Shahrizaila, N. |
Issue Date: | 2011 | Citation: | Yuki, N., Shahrizaila, N. (2011). Guillain-Barré syndrome animal model: The first proof of molecular mimicry in human autoimmune disorder. Journal of Biomedicine and Biotechnology 2011 : -. ScholarBank@NUS Repository. https://doi.org/10.1155/2011/829129 | Abstract: | Molecular mimicry between self and microbial components has been proposed as the pathogenic mechanism of autoimmune diseases, and this hypothesis is proven in Guillain-Barré syndrome. Guillain-Barré syndrome, the most frequent cause of acute neuromuscular paralysis, sometimes occurs after Campylobacter jejuni enteritis. Gangliosides are predominantly cell-surface glycolipids highly expressed in nervous tissue, whilst lipo-oligosaccharides are major components of the Gram-negative bacterium C. jejuni outer membrane. IgG autoantibodies to GM1 ganglioside were found in the sera from patients with Guillain-Barré syndrome. Molecular mimicry was demonstrated between GM1 and lipo-oligosaccharide of C. jejuni isolated from the patients. Disease models by sensitization of rabbits with GM1 and C. jejuni lipo-oligosaccharide were established. Guillain-Barré syndrome provided the first verification that an autoimmune disease is triggered by molecular mimicry. Its disease models are helpful to further understand the molecular pathogenesis as well as to develop new treatments in Guillain-Barré syndrome. Copyright © 2011 Nortina Shahrizaila and Nobuhiro Yuki. | Source Title: | Journal of Biomedicine and Biotechnology | URI: | http://scholarbank.nus.edu.sg/handle/10635/125873 | ISSN: | 11107243 | DOI: | 10.1155/2011/829129 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.